By Karen Blum
Pharmaceutical manufacturers looking to help patients gain access to expensive drug and medical treatments need to review and follow guidance from the Department of Health and Human Services’ Office of Inspector General (OIG), according to panelists speaking at Informa Connect’s 2021 Compliance Congress for Specialty Products, held virtually. Otherwise, they could be at risk for legal action.
JUNE 24, 2021